| Marie Roy Babbitt, MD | |
|
3240 Hospital Dr, Juneau, AK 99801-7808 | |
| (907) 796-8948 | |
| (907) 796-8497 |
| Full Name | Marie Roy Babbitt |
|---|---|
| Gender | Female |
| Speciality | Psychiatry |
| Experience | 9 Years |
| Location | 3240 Hospital Dr, Juneau, Alaska |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205223526 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084P0800X | Psychiatry & Neurology - Psychiatry | 55415 (Arizona) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Bartlett Regional Hospital | 7517950868 | 17 |
News Archive
The new U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule should help healthcare providers better explain to pregnant and breastfeeding patients the benefits and risks of taking a specific medication.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from in vitro and in vivo studies assessing the efficacy of Restanza (cethromycin), its novel oral antibiotic, against the species of Plasmodium that cause malaria.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device.
Boehringer Ingelheim and Eli Lilly and Company today announced Phase III study results for linagliptin, demonstrating improved glycaemic control in adults with type 2 diabetes (T2D) whose blood glucose is not adequately maintained.
› Verified 4 days ago
| Entity Name | Bartlett Regional Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1154331734 PECOS PAC ID: 7517950868 Enrollment ID: O20040405000593 |
News Archive
The new U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule should help healthcare providers better explain to pregnant and breastfeeding patients the benefits and risks of taking a specific medication.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from in vitro and in vivo studies assessing the efficacy of Restanza (cethromycin), its novel oral antibiotic, against the species of Plasmodium that cause malaria.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device.
Boehringer Ingelheim and Eli Lilly and Company today announced Phase III study results for linagliptin, demonstrating improved glycaemic control in adults with type 2 diabetes (T2D) whose blood glucose is not adequately maintained.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Marie Roy Babbitt, MD 3240 Hospital Dr, Juneau, AK 99801-7808 Ph: (907) 796-8948 | Marie Roy Babbitt, MD 3240 Hospital Dr, Juneau, AK 99801-7808 Ph: (907) 796-8948 |
News Archive
The new U.S. Food and Drug Administration's Pregnancy and Lactation Labeling Rule should help healthcare providers better explain to pregnant and breastfeeding patients the benefits and risks of taking a specific medication.
Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from in vitro and in vivo studies assessing the efficacy of Restanza (cethromycin), its novel oral antibiotic, against the species of Plasmodium that cause malaria.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain today announced that it has received CE Mark approval (Conformite Europeenne) for the Zalviso device.
Boehringer Ingelheim and Eli Lilly and Company today announced Phase III study results for linagliptin, demonstrating improved glycaemic control in adults with type 2 diabetes (T2D) whose blood glucose is not adequately maintained.
› Verified 4 days ago
Robert D Schults, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 3260 Hospital Dr, Juneau, AK 99801 Phone: 907-796-8498 Fax: 907-796-8497 | |
Dr. David Benjamin Robinson, M.D., M.P.H. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 2239 Jordan Ave, Juneau, AK 99801 Phone: 907-789-3800 Fax: 907-789-2402 | |
Mr. Paul Jiri Topol, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 2 Marine Way, Suite 204, Juneau, AK 99801 Phone: 907-209-8962 Fax: 866-581-8172 | |
Dr. Susan E Hunter-joerns, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 2205 Jordan Ave, Juneau, AK 99801 Phone: 907-790-3224 Fax: 907-790-3226 | |
Dr. Eli Alexander Woods Oates, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3260 Hospital Dr, Juneau, AK 99801 Phone: 907-796-8900 | |
Alvin J Fineman, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 3240 Hospital Dr, Juneau, AK 99801 Phone: 907-796-8498 Fax: 907-796-8497 |